The intestinal microbiota and immune system are separated by an epithelial layer, whose barrier function is crucial for the healthy state of the host, while its impairment, usually associated with inflammation, leads to a variety of pathologies in humans. Different probiotics targeting the preservation of epithelial barrier homeostasis are thus currently being developed. Their selection and validation are a complex process involving in-vitro and in-vivo models. While the former lacks the complexity of the physiological system, the latter often fails to reflect the effect in humans. We used the commercial microfluidic high-throughput device OrganoPlate to set up a Gut-on-Chip model comprising human epithelial and peripheral blood mononuclear cells (PBMC). As a proof-of-concept, we co-cultured several intestinal anaerobic bacteria species in direct contact with the epithelial monolayer for two days to investigate their impact on epithelial barrier integrity and immune response upon induction of inflammation. We demonstrate here that Bacteroides thetaiotaomicron protects the epithelial barrier and dampens CCL2 secretion provoked by LPS-stimulated PBMC. Recapitulating the key features of intestinal inflammation, we suggest that the current Gut-on-Chip model enables an easy-to-use screen of next-generation probiotics and live biotherapeutics with homeostatic and immunomodulatory properties.
The intestinal microbiota plays a crucial role in maintaining epithelial barrier integrity, while its impairment and the resulting inflammation contribute to numerous human pathologies. To preserve intestinal homeostasis, various probiotics are being developed; however, their selection and validation require accessible yet physiologically relevant models. We recently established a high-throughput Gut-on-Chip model comprising human epithelial (Caco-2) cells and peripheral blood mononuclear cells (PBMCs), demonstrating epithelial barrier disruption and pro-inflammatory cytokine secretion upon inflammation induction. The present study aimed to evaluate the feasibility of co-culturing anaerobic members of the human intestinal microbiota within this model and to assess their effects on inflammation-induced epithelial damage. We successfully co-cultured five intestinal anaerobic bacterial species in direct contact with the epithelial monolayer for two days. As proof of concept, we demonstrate that live Bacteroides thetaiotaomicron and its supernatant preserve epithelial barrier integrity and attenuate CCL2 secretion by Caco-2 cells. In contrast, Clostridium scindens did not prevent epithelial damage but suppressed CCL20 secretion, revealing a promising target for future studies. By recapitulating some of the key aspects of intestinal inflammation, we suggest that the current Gut-on-Chip model has potential as an easy-to-use platform for screening next-generation probiotics and live biotherapeutics with homeostatic and immunomodulatory properties.